NCT06553365View on ClinicalTrials.gov

Phase II Study of FCN-159 in NF2 Nerve Sheath Tumors

PHASE2RecruitingINTERVENTIONAL

Enrollment

30

Participants

Timeline

Start Date

August 15, 2024

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

Nerve Sheath Tumor

Interventions

DRUG

FCN-159

FCN-159 8mg qd po

Trial Locations (1)

100021

RECRUITING

Shuhang Wang, Beijing

All Listed Sponsors

lead

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

OTHER